FY2027 Earnings Forecast for Biogen Issued By William Blair

Biogen Inc. (NASDAQ:BIIB - Free Report) - Equities research analysts at William Blair cut their FY2027 EPS estimates for shares of Biogen in a research report issued to clients and investors on Wednesday, April 23rd. William Blair analyst M. Minter now forecasts that the biotechnology company will post earnings per share of $16.77 for the year, down from their prior estimate of $17.41. William Blair has a "Outperform" rating on the stock. The consensus estimate for Biogen's current full-year earnings is $15.83 per share. William Blair also issued estimates for Biogen's FY2028 earnings at $17.66 EPS and FY2029 earnings at $18.03 EPS.

A number of other equities research analysts have also recently commented on the company. Argus cut Biogen from a "buy" rating to a "hold" rating in a research report on Friday, April 4th. HC Wainwright decreased their target price on Biogen from $300.00 to $241.00 and set a "buy" rating on the stock in a research report on Thursday, February 13th. Needham & Company LLC reissued a "hold" rating on shares of Biogen in a report on Friday. Royal Bank of Canada increased their price objective on shares of Biogen from $221.00 to $225.00 and gave the company an "outperform" rating in a report on Tuesday, April 22nd. Finally, Bank Of America (Bofa) cut their target price on shares of Biogen from $178.00 to $163.00 and set a "neutral" rating for the company in a research note on Tuesday, February 11th. Nineteen equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company's stock. Based on data from MarketBeat, Biogen currently has a consensus rating of "Hold" and a consensus price target of $203.07.

Biogen Stock Performance

Shares of NASDAQ BIIB traded up $0.28 during midday trading on Friday, reaching $119.12. 1,345,394 shares of the stock were exchanged, compared to its average volume of 1,350,270. The firm has a market cap of $17.44 billion, a price-to-earnings ratio of 10.65, a PEG ratio of 1.51 and a beta of 0.06. The company has a quick ratio of 0.90, a current ratio of 1.35 and a debt-to-equity ratio of 0.27. The firm has a 50-day simple moving average of $132.47 and a two-hundred day simple moving average of $148.86. Biogen has a twelve month low of $110.04 and a twelve month high of $238.00.

Biogen (NASDAQ:BIIB - Get Free Report) last released its quarterly earnings data on Wednesday, February 12th. The biotechnology company reported $3.44 earnings per share for the quarter, beating analysts' consensus estimates of $3.43 by $0.01. Biogen had a return on equity of 14.98% and a net margin of 16.87%.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in BIIB. Inspire Trust Co. N.A. increased its holdings in shares of Biogen by 58.5% in the 3rd quarter. Inspire Trust Co. N.A. now owns 10,900 shares of the biotechnology company's stock valued at $2,113,000 after acquiring an additional 4,025 shares during the period. Assenagon Asset Management S.A. raised its holdings in shares of Biogen by 0.3% in the fourth quarter. Assenagon Asset Management S.A. now owns 43,460 shares of the biotechnology company's stock valued at $6,646,000 after buying an additional 111 shares during the last quarter. Amundi grew its holdings in shares of Biogen by 35.6% during the fourth quarter. Amundi now owns 1,216,990 shares of the biotechnology company's stock worth $183,461,000 after buying an additional 319,478 shares during the last quarter. Centre Asset Management LLC raised its stake in Biogen by 7.7% during the 4th quarter. Centre Asset Management LLC now owns 51,530 shares of the biotechnology company's stock valued at $7,880,000 after acquiring an additional 3,698 shares during the last quarter. Finally, Integrated Quantitative Investments LLC acquired a new stake in Biogen during the 4th quarter worth approximately $407,000. Hedge funds and other institutional investors own 87.93% of the company's stock.

Insiders Place Their Bets

In other Biogen news, Director Stephen A. Sherwin sold 8,760 shares of the company's stock in a transaction on Friday, March 7th. The shares were sold at an average price of $150.02, for a total value of $1,314,175.20. Following the completion of the transaction, the director now owns 11,318 shares in the company, valued at $1,697,926.36. This represents a 43.63 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 0.16% of the stock is owned by corporate insiders.

About Biogen

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.